MedTrace Logo

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

NCT04492033 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2025-01-27

No results posted yet for this study

Summary

This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.

Conditions

  • P1b: Advanced Solid Tumors
  • P2: Biliary Tract Cancer

Interventions

DRUG

CTX-009 (ABL001)

CTX-009 (ABL001) will be administered biweekly.

DRUG

Paclitaxel

Paclitaxel will be administered weekly.

DRUG

Irinotecan

Irinotecan will be administered biweekly.

Sponsors & Collaborators

  • Compass Therapeutics

    collaborator INDUSTRY

  • ABL Bio, Inc.

    collaborator INDUSTRY

  • Handok Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2024-01-08
Completion
2025-01-09
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492033 on ClinicalTrials.gov